| Ticker: ALXN | 25 Science Park | |
| Exchange: NASDAQ-National Market | New Haven, Connecticut 06511 | |
| Industry: Manufacturing | (203) 776-1790 |
| Type of Shares: | Common Shares | Filing Date: | 1/11/96 | |
| U.S. Shares: | 2,200,000 | Offer Date: | 2/28/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $9.00 | |
| Primary Shares: | 2,200,000 | Offer Price: | $8.25 | |
| Secondary Shares: | 0 | Gross Spread: | $0.58 | |
| Offering Amount: | $18,700,000 | Selling: | $0.34 | |
| Expenses: | $997,250 | Reallowance: | $0.10 | |
| Shares Out After: | 6,982,383 |
| Manager | Tier | Phone |
| Josephthal Lyon & Ross, Inc. | Lead Manager | (212) 907-4564 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 7/31/95 | 10/31/95 | 10/31/94 | 10/31/95 | ||
| Revenue: | $0.14 | $0.45 | $0.00 | Assets: | $5.89 |
| Net Income: | -$7.12 | -$1.29 | -$1.97 | Liabilities: | $2.10 |
| EPS: | $1.76 | -$0.29 | -$0.48 | Equity: | $3.79 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company engaged in research and development of proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The company is developing C5 complement inhibitors and Apogens, two classes of potential therapeutic compounds designed to selectively target specific disease causing segments of the immune system. The company believes that its C5 Inhibitors and Apogens, which are based upon immunoregulatory technologies, may have the advantage of achieving a higher level of efficacy with the potential for reduced side effects when compared to existing therapeutics approaches. The company anticipates it will file an Investigational New Drug Application for its first C5 Inhibitor product candidate, targeting the prevention of inflammation during cardiopulmonary bypass procedures, in the first quarter of 1996 and will thereafter commence clinical trials. The company anticipates that it will file an IND for its lead proprietary Apogen, MP4, for treatment of multiple sclerosis, in late 1996. |
| Use of Proceeds |
| The proceeds from the offering will be used to fund the company's research and development including preclinical and clinical studies and early stage manufacturing, to pay certain licensing fees and royalties, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.